Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ContraFect Co. stock logo
CFRX
ContraFect
$0.05
$0.05
$0.04
$13.02
$535K0.291.39 million shs910,216 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$2.85
+13.5%
$1.74
$0.73
$3.90
$180.38M0.7415,594 shs504,866 shs
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
$0.05
-8.6%
$0.10
$0.03
$10.79
$279K1.4249.01 million shs121.43 million shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$2.64
-6.0%
$2.07
$0.51
$3.22
$147.60M1.331.22 million shs909,238 shs
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$7.00
$7.10
$4.07
$7.70
$294.54M0.99133,095 shs12,421 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ContraFect Co. stock logo
CFRX
ContraFect
0.00%0.00%0.00%0.00%0.00%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
+13.55%+32.56%+108.03%+112.69%+27.23%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-8.57%-8.02%-60.05%-94.63%-98.54%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-6.05%-8.97%-6.71%+254.65%+86.57%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.2764 of 5 stars
3.52.00.00.03.31.70.0
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
3.2241 of 5 stars
3.33.00.00.02.92.51.3
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
3.9687 of 5 stars
3.33.00.04.72.70.00.6
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ContraFect Co. stock logo
CFRX
ContraFect
0.00
N/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.00110.53% Upside
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
2.50
Moderate Buy$25.0054,366.23% Upside
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.50
Moderate Buy$5.0089.39% Upside
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CFRX, TLC, GALT, SPRO, and NCNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/A($19.92) per shareN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/A$1.34 per shareN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$47.98M3.08N/AN/A$0.85 per share3.11
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$3.63M81.14N/AN/A$0.83 per share8.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ContraFect Co. stock logo
CFRX
ContraFect
-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/A

Latest CFRX, TLC, GALT, SPRO, and NCNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.16N/AN/AN/AN/AN/A
8/4/2025Q2 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.35N/AN/AN/AN/AN/A
6/2/2025Q1 2025
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
-$0.0129-$0.63-$0.6171-$0.63N/AN/A
5/15/2025Q1 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.20-$0.15+$0.05-$0.15N/AN/A
5/13/2025Q1 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/AN/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ContraFect Co. stock logo
CFRX
ContraFect
N/A
0.53
0.53
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
0.08
0.08
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
N/A
1.25
1.25
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/A
2.56
2.56
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.67
3.01
3.01

Institutional Ownership

CompanyInstitutional Ownership
ContraFect Co. stock logo
CFRX
ContraFect
7.85%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
44.00%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25.60%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.22%

Insider Ownership

CompanyInsider Ownership
ContraFect Co. stock logo
CFRX
ContraFect
0.62%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
50.10%
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
31.20%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
5.50%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ContraFect Co. stock logo
CFRX
ContraFect
2310.70 million10.64 millionNot Optionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.29 million31.58 millionOptionable
NuCana PLC Sponsored ADR stock logo
NCNA
NuCana
306.08 million4.18 millionNot Optionable
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
15055.91 million52.84 millionOptionable
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
2,02042.08 millionN/ANot Optionable

Recent News About These Companies

What is the TLC Diet?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ContraFect stock logo

ContraFect NASDAQ:CFRX

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$2.85 +0.34 (+13.55%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$2.85 0.00 (0.00%)
As of 07/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

NuCana stock logo

NuCana NASDAQ:NCNA

$0.05 0.00 (-8.57%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$0.05 +0.00 (+3.92%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Spero Therapeutics stock logo

Spero Therapeutics NASDAQ:SPRO

$2.64 -0.17 (-6.05%)
Closing price 07/14/2025 04:00 PM Eastern
Extended Trading
$2.63 -0.01 (-0.38%)
As of 07/14/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Taiwan Liposome stock logo

Taiwan Liposome NASDAQ:TLC

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.